Hypofractionated vs Standard Radiation for Glioblastoma

When you or someone you love is newly diagnosed with glioblastoma (GBM), the radiation planning conversation can feel overwhelming. Your oncologist may present two main scheduling options: standard fractionation - a six-week course - or hypofractionated radiation, which compresses treatment into two to three weeks. Both target the tumor with ionizing radiation. The question is which schedule fits the patient's age, health status, molecular markers, and practical situation. This article explains how the two approaches work, what the evidence shows, and how to think through the decision with your care team.

What Is Standard Radiation for Glioblastoma?

Standard radiation for GBM delivers a total dose of 60 gray (Gy) in 30 daily sessions over six weeks, with 2 Gy given per session. This schedule runs Monday through Friday and typically pairs with daily oral temozolomide (TMZ) chemotherapy. Together, this is the Stupp protocol, named after the landmark 2005 trial that showed the combination improved median survival compared to radiation alone in patients up to age 70 with good performance status.

The six-week schedule balances effective tumor control against damage to surrounding healthy brain tissue. Smaller daily doses give normal cells time to recover between sessions - a principle called fractionation - which matters when treating a brain tumor surrounded by critical structures.

For a newly diagnosed patient under 65 with a good performance status - meaning they can largely care for themselves and carry out daily activities - this remains the standard choice. Doctors often combine it with Tumor Treating Fields (TTFields), a wearable scalp device that uses alternating electric fields to disrupt tumor cell division. A randomized trial showed that adding TTFields to the Stupp protocol extended median overall survival compared to the protocol alone.

What Is Hypofractionated Radiation?

Hypofractionated radiation delivers the same therapeutic goal in fewer, larger daily doses. The most widely used schedule is 40 Gy in 15 fractions over three weeks, though some centers use even shorter courses such as 25 Gy in five fractions over one week. Because each fraction carries a larger biological effect, the total number of sessions drops significantly.

Doctors first explored hypofractionation to spare older and frailer patients the physical burden of a six-week daily hospital commute. A six-week schedule is demanding for anyone, but for a 78-year-old with heart disease or limited mobility, it can be genuinely impractical. Shorter courses can achieve survival outcomes comparable to the standard schedule in selected patients without meaningfully increasing brain toxicity.

Doctors now routinely add temozolomide to hypofractionated radiation in eligible patients, based on the Perry et al. 2017 randomized phase III trial published in the New England Journal of Medicine. That trial found that combining short-course radiation with TMZ extended survival in elderly GBM patients compared to short-course radiation alone.

How Do Standard and Hypofractionated Radiation Compare?

Sources: Current Standards of Care in Glioblastoma Therapy (NCBI Bookshelf); Perry et al., NEJM 2017; Malmstrom et al., Lancet Oncology 2012 (Nordic trial).

The key finding from head-to-head trials is that for older or frailer patients, hypofractionated radiation with temozolomide achieves survival results similar to the full six-week course. The shorter schedule is an evidence-based alternative tailored to a specific group of patients, not a fallback option. For younger patients with good performance status, standard fractionation remains the benchmark.

Who Is Hypofractionated Radiation Best Suited For?

Radiation oncologists typically consider a shorter schedule when one or more of the following apply:

• Age 65 or older. The major randomized trials testing hypofractionation specifically enrolled patients aged 60 and older. The Perry 2017 trial included patients with a median age of 73.
• Reduced performance status. A Karnofsky Performance Score (KPS) below 70 - meaning the patient needs some assistance with daily activities - signals that a long treatment course may carry unacceptable burden or risk.
• Significant comorbidities. Heart disease, diabetes, kidney impairment, or other serious conditions can reduce a patient's ability to tolerate six weeks of daily radiation safely.
• Logistical constraints. Living far from a radiation center, or having limited transport or family support, can make a three-week schedule meaningfully more feasible than six weeks.
• Patient and family preference. Some patients and families prioritize limiting the time spent in hospital-based treatment. Your values belong in this conversation.

Age alone doesn't determine the decision. A 68-year-old who is physically fit, fully independent, and lives near a cancer center may be a better candidate for standard fractionation than a 62-year-old with serious heart disease recovering from surgery. Your oncologist will weigh performance status, comorbidities, and tumor biology together.

Does MGMT Methylation Change the Answer?

Yes - and this is one of the most important data points your pathology report provides.

MGMT (O6-methylguanine-DNA methyltransferase) is a DNA-repair enzyme. When the MGMT gene promoter is methylated, the tumor produces less of this enzyme, which means temozolomide can damage tumor DNA more effectively. Patients with MGMT-methylated tumors consistently show longer survival when treated with TMZ-based regimens, regardless of whether they receive standard or hypofractionated radiation.

In the Perry 2017 trial, adding TMZ to short-course radiation produced the greatest survival benefit in MGMT-methylated patients. For patients with MGMT-unmethylated tumors, the benefit of adding TMZ is smaller, though doctors still frequently use it because individual responses vary.

If your pathology report's MGMT result is unclear, or if you want to understand what the other molecular markers mean, understanding your glioblastoma pathology report is a useful next step before your next oncology appointment. This single biomarker can meaningfully shape both which radiation schedule and which drugs are most likely to help.

What About Patients Under 65?

For younger patients - typically those under 65 with good performance status - standard fractionation (60 Gy over six weeks) with concurrent and adjuvant TMZ remains the benchmark. The Stupp protocol trials that established this standard enrolled patients up to age 70, and the six-week schedule has the strongest evidence base for this age and fitness profile.

Doctors don't usually recommend hypofractionation for younger, fitter patients as a first choice. However, exceptions exist. A younger patient with a very large tumor, poor performance status at the time of diagnosis, or a significant comorbidity may still be a candidate for a shorter course.

For eligible newly diagnosed patients, doctors often recommend Tumor Treating Fields alongside the Stupp protocol. If you're weighing whether TTFields fit into your overall treatment plan, the article on how Tumor Treating Fields work in glioblastoma explains the device, the evidence, and practical considerations for wearing it daily.

What the Perry 2017 Trial Found

The Perry et al. trial - published in the New England Journal of Medicine in 2017 - is the most directly relevant evidence for elderly patients considering these two schedules. It enrolled 562 patients with a median age of 73 and randomized them to short-course radiation (40 Gy in 15 fractions) alone or short-course radiation plus TMZ. The trial found that adding TMZ to short-course radiation improved median overall survival from 7.6 months to 9.3 months across the full study population. In MGMT-methylated patients, the survival gain was larger.

This trial answered one of the key practical questions in elderly GBM care: even with a compressed radiation schedule, adding temozolomide helps if the patient can tolerate the drug. Before this trial, some clinicians had doubts about whether the combination made sense outside the full six-week protocol.

The earlier Nordic randomized trial (Malmstrom et al., Lancet Oncology, 2012) compared standard radiation, hypofractionated radiation, and temozolomide alone in patients over 60 years. It found that hypofractionated RT performed at least as well as standard RT in elderly patients, and that TMZ alone was competitive in MGMT-methylated patients. The Nordic trial helped establish that the six-week course does not carry a survival advantage over hypofractionation in older patients - and may carry more burden without adding benefit.

Questions to Bring to Your Radiation Oncologist

Whether you are the patient or a caregiver, these questions can sharpen the conversation:

• What is the patient's current Karnofsky Performance Score, and how does it factor into the radiation recommendation?
• Has the MGMT methylation result come back, and how does it affect the decision about adding temozolomide?
• Why is hypofractionation being considered - because of age, health status, logistics, or a combination?
• If hypofractionation is being recommended, which specific schedule is your team planning and why?
• What side effects should we expect from each schedule, and how do they differ in timing and severity?
• Will your team recommend TTFields after radiation, and what does that transition look like?
• Is there an open clinical trial that involves a modified radiation schedule or an additional agent alongside radiation?

Getting a Second Opinion on Your Radiation Plan

Radiation planning decisions can differ between centers - not because one team is wrong, but because evidence-based protocols leave room for clinical judgment, and that judgment reflects a team's experience and case volume. If you are unsure whether the recommended schedule fits the patient's full clinical picture, it makes sense to have it reviewed before committing. You can arrange a remote second opinion through Art of Healing Cancer, whose team can review pathology reports, MRI imaging, and the proposed radiation plan with experienced neuro-oncologists before treatment begins.

If you are ready to have your case reviewed, you can upload your scan reports and pathology documents at the Glioblastoma Center patient journey form to request a remote case review. For help getting through the first weeks after diagnosis, see the guide on what to do in your first 30 days after a glioblastoma diagnosis, which covers the practical steps in sequence.

When to Talk to Your Doctor

Raise the radiation schedule question with your neuro-oncologist or radiation oncologist before planning is finalized - especially if:

• You are unsure which schedule has been recommended and why.
• The MGMT methylation result has not yet come back and you want to wait for it before finalizing the plan.
• The patient's performance status has changed since surgery.
• You are traveling internationally and a three-week schedule would significantly ease the logistics of your stay.
• You want to understand clinical trial options that may involve a modified radiation schedule.

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.